<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_m9QmDv8">Specific hypertension smartphone application to improve medication adherence in hypertension: a cluster-randomized trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Emilio</forename><surname>M Arquez Contreras</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>a</label> Molino de la Vega Health Center , Huelva , Spain;</note>
								<orgName type="institution">Molino de la Vega Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sara</forename><forename type="middle">M</forename><surname>Arquez Rivero</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>a</label> Molino de la Vega Health Center , Huelva , Spain;</note>
								<orgName type="institution">Molino de la Vega Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>b</label> La Orden Health Center , Huelva , Spain ;</note>
								<orgName type="institution">La Orden Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elizabeth</forename><surname>Rodr Iguez Garc Ia</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lourdes</forename><surname>L Opez-Garc Ia-Ramos</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Carlos</forename><surname>Pastoriza Vilas</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>c</label> San Juan del Puerto Health Center , Huelva , Spain;</note>
								<orgName type="institution">San Juan del Puerto Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>d</label> Adoratrices Health Center , Huelva , Spain ;</note>
								<orgName type="department">Adoratrices Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>e</label> Universidad de Elx , Alicante , Spain;</note>
								<orgName type="institution">Universidad de Elx</orgName>
								<address>
									<settlement>Alicante</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Agueda</forename><surname>Baldonedo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Su</forename><surname>Arez</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>a</label> Molino de la Vega Health Center , Huelva , Spain;</note>
								<orgName type="institution">Molino de la Vega Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carmen</forename><forename type="middle">Gracia</forename><surname>Diez</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>a</label> Molino de la Vega Health Center , Huelva , Spain;</note>
								<orgName type="institution">Molino de la Vega Health Center</orgName>
								<address>
									<settlement>Huelva</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vicente</forename><surname>Gil Guill En E</surname></persName>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>e</label> Universidad de Elx , Alicante , Spain;</note>
								<orgName type="institution">Universidad de Elx</orgName>
								<address>
									<settlement>Alicante</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nieves</forename><forename type="middle">Martell</forename><surname>Claros</surname></persName>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>f</label> Unidad de Hipertension , Intern Medicine , San Carlos Hospital , Medicine University , UCM Madrid , Spain</note>
								<orgName type="department" key="dep1">Unidad de Hipertension</orgName>
								<orgName type="department" key="dep2">Intern Medicine</orgName>
								<orgName type="institution" key="instit1">San Carlos Hospital</orgName>
								<orgName type="institution" key="instit2">Medicine University</orgName>
								<orgName type="institution" key="instit3">UCM Madrid</orgName>
								<address>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Emilio</forename><forename type="middle">M</forename><surname>Arquez Contreras</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Compliance Group of Spanish Society of Hypertension (SEH-LELHA )</note>
								<orgName type="laboratory">Compliance Group of Spanish Society of Hypertension (SEH-LELHA</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">C/Puerto , 7 , 6 D , Huelva -21003 , Spain</note>
								<orgName type="institution">C/Puerto</orgName>
								<address>
									<addrLine>7 6 D</addrLine>
									<postCode>-21003</postCode>
									<settlement>Huelva</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_DyMFqa8">Specific hypertension smartphone application to improve medication adherence in hypertension: a cluster-randomized trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B995FEF685F531C07114BE103286A26F</idno>
					<idno type="DOI">10.1080/03007995.2018.1549026</idno>
					<note type="submission">Received 17 July 2018 Accepted 9 November 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T13:59+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_eKewUwN">Hypertension</term>
					<term xml:id="_azRpPuf">drug adherence</term>
					<term xml:id="_b588rb2">smartphone app</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_rgQZ3m2"><p xml:id="_ffH6bNa"><s xml:id="_Pg9GDa8">Introduction: Digital interventions, such as smartphone applications (apps), are becoming an increasingly common way to support medication adherence and self-management in chronic illness.</s><s xml:id="_wJsYvjk">Aim: To evaluate the effectiveness of the intervention in pharmacological therapeutic adherence in mild to moderate arterial hypertension (AHT), through an app installed on a mobile phone, as well as the degree of control reached by the patient with this tool.</s><s xml:id="_C676CmC">Methods: Prospective, randomized controlled trial, full study and multicenter study.</s><s xml:id="_v7TnTuf">Four primary care centers participated.</s><s xml:id="_qdBtj8u">One hundred and fifty-four hypertensive patients under antihypertensive treatment were included.</s><s xml:id="_HD29UpG">Two groups were established: a control group (CG) with usual intervention (n ¼ 77) and an intervention group (n ¼ 77) (IG), targeting hypertensive people who owned and regularly used a mobile smartphone, specifically using the app called AlerHTA to promote health education and reminder of appointments.</s><s xml:id="_xGw5sb4">There were three visits: initial, 6 and 12 months.</s><s xml:id="_KEuKVHz">Drug adherence was measured by electronic monitors (MEMSs).</s><s xml:id="_CcN33QE">The primary outcomes were average daily percentage adherence between 80 and 100%, and AHT control.</s><s xml:id="_CVyRv5v">Results: A total of 148 patients finished the study.</s><s xml:id="_vZuQeef">Mean age was 57.5 ± 9.9.</s><s xml:id="_Cb4XSVT">Global adherence was 77.02% (CI ¼ 70.25-83.79)</s><s xml:id="_dG9XeUC">and daily adherence was 74.32% (CI ¼ 67.29-81.35%).</s><s xml:id="_RNJkjhz">Daily adherence was 93.15% and 86.3% in IG, and 70.66% and 62.66% in CG after 6 and 12 months respectively (p &lt; .05).</s><s xml:id="_WKATZVb">The percentage of uncontrolled patients was 28.3% (CI ¼ 21.05-35.55%).</s><s xml:id="_Xhc7Vpt">The control of high blood pressure at 12 months was 17.8% and 38.6% for IG and CG respectively (p &lt; .05).</s><s xml:id="_4hhg8wA">The number of patients needed to treat to avoid non-adherence (NNT) was 4.23 patients.</s><s xml:id="_FVhb63H">Conclusions: The intervention with an app installed on the mobile phones of hypertensive patients favors pharmacological therapeutic adherence and improves the percentage of hypertensive patient control.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="634.32" lry="833.04"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="609.449" lry="793.701"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_twm8z6t">Introduction</head><p xml:id="_K6K3R6B"><s xml:id="_yehBhbT">Arterial hypertension (AHT) is one of the main health problems worldwide, because it is considered a major risk factor for cardiovascular, cerebrovascular and renal diseases <ref type="bibr" target="#b0">1</ref> .</s><s xml:id="_MZq9D2x">Blood pressure (BP) control through pharmacological treatment has led to substantial benefits in the prevention of morbidity and mortality from cardiovascular disease <ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_ZcTDdz8">Despite the efficacy of antihypertensive agents, there is a significant problem of non-adherence to these medications in those diagnosed with hypertension, which limits the effectiveness of current treatments.</s><s xml:id="_HdfQUhm">The consequences of non-adherence are serious because of the resulting poor clinical outcomes and preventable health care costs.</s></p><p xml:id="_b3Wah66"><s xml:id="_n9gAyGJ">The relationship between drug failure and inadequate BP control is well known, since nearly 75% of non-adherent patients do not achieve optimal BP <ref type="bibr" target="#b2">3</ref> .</s><s xml:id="_JzKAfyV">Antihypertensive adherence can reduce the risk of stroke by 35-40% and myocardial infarction by 20-25% <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> .</s><s xml:id="_2QV4Tnd">However, a study encompassing the findings of 28 studies of 15 countries showed that 45.2% of hypertensives failed the treatment <ref type="bibr" target="#b5">6</ref> .</s><s xml:id="_cZqWfGR">In Spain, antihypertensive non-adherence ranges between 7.1% and 66.2% <ref type="bibr" target="#b6">7</ref> .</s></p><p xml:id="_WgDg9BA"><s xml:id="_q2MvF7S">The term therapeutic adherence is "the extent to which the patient assumes the rules or advice given by the doctor or health personnel, both from the point of view of recommended habits or lifestyle and the prescribed pharmacological treatment itself.</s><s xml:id="_gA82jwJ">It is expressed itself with it the degree of coincidence between the orientations given by the professional and the realization by the patient, made after a decision fully reasoned by the latter" <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8</ref> .</s></p><p xml:id="_XCTRCwa"><s xml:id="_dBU5QdF">Different studies and systematic reviews have assessed the relevance of different interventions in the improvement of therapeutic adherence <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref> .</s><s xml:id="_DJtnPez">However, the conclusions of epidemiological studies on the effectiveness of the intervention differ widely.</s><s xml:id="_JWN4ZRx">Importantly, forgetting, i.e. not remembering, has been found to be the most common reason for patients not taking medication <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> .</s></p><p xml:id="_Q5D4GfY"><s xml:id="_eEaWQU3">Worldwide, the mobile phone has become the preferred tool for communication and access to information <ref type="bibr" target="#b13">14</ref> .</s><s xml:id="_yMuBquw">One of the strategies that can facilitate adherence could be the integration of the hypertensive patient's mobile phone in the provision of healthcare.</s></p><p xml:id="_7XhEyzy"><s xml:id="_WsK6K4S">There are studies that have assessed the effectiveness of SMS text messages in improving adherence.</s><s xml:id="_kQQkhQA">Some, but not all studies, suggest that reminder SMS messages can improve clinic attendance and the subjective perception of adherence to medication <ref type="bibr" target="#b14">15</ref> .</s><s xml:id="_vcEWeXS">Two other clinical trials with short follow-up periods have explored the efficacy of SMS-based interventions to improve treatment adherence and control BP.</s><s xml:id="_cqAknu9">Although the results of the trials indicate small to moderate effects in improving adherence and control of BP, the results were not statistically significant <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17</ref> .</s></p><p xml:id="_hQK9NkK"><s xml:id="_eKSFvAE">Kumar et al. <ref type="bibr" target="#b17">18</ref> focused on apps for hypertension management and found that these apps contained tools specifically for medication adherence (e.g.</s><s xml:id="_N6cz3G5">pill reminders) and also performed a BP-tracking function through a wireless BP monitor.</s><s xml:id="_ujsPEjb">Green <ref type="bibr" target="#b18">19</ref> claimed that the innovative smartphone apps offer a new strategy for patients and their families to be more actively involved in hypertension self-care.</s></p><p xml:id="_3Zcam6U"><s xml:id="_5aSuvq8">However, we must consider whether these new technologies may also have the potential to create an undesirable burden for the patients and it remains unclear whether these technologies are feasible, acceptable and usable in the context of self-control of hypertension <ref type="bibr" target="#b19">20</ref> .</s></p><p xml:id="_yERvz9X"><s xml:id="_rrVQjXG">In this sense, Morrissey et al. <ref type="bibr" target="#b20">21</ref></s><s xml:id="_jJaQGZs">, studying how patients engage with these technologies, demonstrated that patients can identify the benefits of a medication reminder and recognize that self-monitoring their blood pressure could be empowering their understanding of the condition and improve interactions with their general practitioners.</s></p><p xml:id="_k3cx8Wz"><s xml:id="_HZWzFMG">Our objective was to evaluate the effectiveness of an app installed on patients' mobile phones on pharmacological adherence and control of BP in patients with mild to moderate arterial hypertension.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cbcG3B6">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_teKrAXy">Design</head><p xml:id="_5Ap2wKe"><s xml:id="_4CRcYJz">An observational, prospective, randomized controlled trial, full study and multicenter study was designed, involving 154 patients treated with an antihypertensive drug for the treatment of mild to moderate arterial hypertension, according to usual clinical practice.</s><s xml:id="_huHNj2w">The study was carried out in four primary care centers in Huelva, involving 22 researchers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JJzk2fc">Calculation of the sample size</head><p xml:id="_9Ek2bGu"><s xml:id="_HMu6gVp">The necessary sample size was calculated for studies that have proportions as main results and requite analysis by bilateral contrast.</s><s xml:id="_zHFrRBf">Differences of 25% 8 of non-adherence between the groups and an estimated prevalence of nonadherence of 35% in the control group were considered of clinical value.</s><s xml:id="_GYAbfpF">Losses of 10% were considered possible, resulting in a sample of 77 individuals in each of the two groups.</s><s xml:id="_YxeeBmM">The final whole sample was 154 patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JKxTJmE">Randomization</head><p xml:id="_uyCDtxu"><s xml:id="_vp9tAat">Cluster randomization was performed.</s><s xml:id="_NfMDkMs">Researchers were randomized, their patients being assigned to the control or intervention group.</s><s xml:id="_gC34ceJ">The randomization was carried out in a centralized manner, by an independent person and using random number tables.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FCBeuBv">Intervention groups</head><p xml:id="_SfBTgnE"><s xml:id="_3vm4Y5s">The groups were:</s></p><p xml:id="_cZkGxET"><s xml:id="_PvPeuWj">1. Control group (CG): 77 patients, who received the usual intervention in HBP (control every 6 months of blood pressure, annual control of therapeutic adherence, annual analysis and biannual electrocardiogram).</s><s xml:id="_taS5Ptz">2. Intervention group (IG): 77 patients who owned and used a mobile phone with iPhone or Android systems.</s><s xml:id="_NvqhYaq">A free app was installed on their mobile phones with the aim of promoting health education in AHT and reminders of both appointments and medication intake time.</s><s xml:id="_TTms56P">This app is called AlerHTA: it has been specially created for the Hypertensive Club of the Spanish Society of Hypertension (SEH-LELHA).</s><s xml:id="_Evy5RwT">It is easily accessible and free to obtain.</s><s xml:id="_nurTzQv">After the patients downloaded the application, the physician instructed them on how to use it and they were given, in addition, the operating instructions of the app in writing.</s><s xml:id="_BjnCfCk">The app allows you to record personal data, recommended BP levels as objectives, the doctor's advice about the prescribed treatment and posology, and set reminder alarms, a calendar of appointments or events, and record the results of the BP measurement.</s></p><p xml:id="_Ck9Z6yz"><s xml:id="_SWuAC74">Medication Event Monitoring Systems (MEMSs) are electronic monitoring devices that use a digital record in the form of a microchip in the lid of the drug container that automatically controls its opening and registers the time and date.</s><s xml:id="_kZn45hZ">Through this method we measured how many times the MEMSs were opened, assuming that one pill was taken with each opening.</s></p><p xml:id="_ccPKZBc"><s xml:id="_2GJawsp">The study lasted 18 months, with an inclusion period of 6 months and a follow-up of 12 months (January 2016 to June 2017).</s><s xml:id="_TXAwYQ4">The selection of patients was made consecutively.</s><s xml:id="_Wye65ss">The researcher enrolled the first seven patients attending her or his service, and they were included in the study on the same day.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KJ2CQKV">Inclusion and exclusion criteria</head><p xml:id="_a3qaqtT"><s xml:id="_3FjqKBM">The inclusion criteria were: (1) outpatients aged over 18 years; (2) patients diagnosed with mild to moderate hypertension (ESH-ESC 2013 criteria), in pharmacological treatment with an antihypertensive tablet at least 1 month before its inclusion.</s></p><p xml:id="_bEy8qYM"><s xml:id="_hZ6UZJx">Exclusion criteria were: (1) pregnant or lactating women; (2) patients whose pathological situation could interfere with the development of the study (acute myocardial infarction, cognitive impairment, terminal illness, etc.); (3) participants in other research studies; (4) hypertensive patients who had a partner taking the same antihypertensive medication.</s></p><p xml:id="_jS7Pr5J"><s xml:id="_uBbXKwr">Patients could be withdrawn from the study when the treating physician considered an increase of more than 30% of the visits originally programmed in the study.</s><s xml:id="_yRQWVgZ">Patients who lost or did not use the MEMS and those who decided not to continue with the study at some point were also withdrawn.</s></p><p xml:id="_rcMsRbJ"><s xml:id="_ydqk866">In the case of abandonment/modification of the prescribed antihypertensive drug at the beginning of the study, patients were not excluded from the study.</s><s xml:id="_tRq5ZXb">In this case, the prescribed antihypertensive agents were introduced into the MEMSs again.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_V8awpMG">Visits and measurements</head><p xml:id="_cGXGB4E"><s xml:id="_MjP6RbH">Three visits took place: the inclusion visit plus two follow-up visits after 6 and 12 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1." xml:id="_fbG3yk2">Inclusion visit: during the inclusion visit written informed</head><p xml:id="_D3waMYY"><s xml:id="_Twd3se5">consent was obtained and clinical anamnesis was done.</s><s xml:id="_pwZjUAT">BP was determined twice in the same arm with semiautomatic sphygmomanometer; weight, height and abdominal circumference were measured too.</s><s xml:id="_aD9C67K">Each patient was provided with one MEMS.</s><s xml:id="_wWqUEyD">Patients had to take a daily dose of antihypertensive medication, between 7 and 9 o'clock in the morning.</s><s xml:id="_PQu2GP4">2. Follow-up and final visits: BP was determined on two occasions, with weight and waist circumference.</s><s xml:id="_G8YF8wk">The investigator could modify the antihypertensive treatment or its dose according to its usual practice.</s><s xml:id="_PHtKhCm">At the end, the MEMSs were evaluated and a patient adherence report was issued.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_asvPSb3">Variables</head><p xml:id="_KkU4QqP"><s xml:id="_ztj3Pxv">The average adherence percentage (AP) was calculated using the following formula:</s></p><p xml:id="_jRWZRp3"><s xml:id="_g6DfPb5">AP ¼ Total number of tablets assumed to have been taken</s></p><p xml:id="_SthFFNQ"><s xml:id="_hjjV9Gg">Total number of tablets that should have been taken Â 100</s></p><p xml:id="_9Vz9jmE"><s xml:id="_rFtqe5f">The individual with AP between 80% and 100% was considered adherent.</s><s xml:id="_Krmdyce">The final AP of the study was considered for each patient and we study the AP accumulated at the time of the end of the follow-up (at the end of the last visit or when the patients were withdrawn from the study).</s></p><p xml:id="_X3s5Nfv"><s xml:id="_Rxp4jNp">Mean AP was calculated using the MEMSs as: (a) global percentage of doses taken (global AP)percentage of all doses taken in an established period; (b) percentage of correct days (daily AP)percentage of days on which antihypertensive drugs were taken correctly (one daily dose); (c) percentage of correct time (time AP)percentage of patients taking the medication at the prescribed time (dosage taken at the recommended time, between 7 and 9 am); (d) percentage of therapeutic cover -AP of therapeutic coverage assuming a 24 hour therapeutic effect of antihypertensive drugs.</s></p><p xml:id="_hxUPTUV"><s xml:id="_z8xDv3s">Adherence was defined as: (a) global adherenceglobal AP between 80 and 100%; (b) daily adherencedaily AP between 80 and 100%; (c) correct time adherencetime AP between 80 and 100%; (d) therapeutic cover adherencetherapeutic cover AP between 80 and 100%.</s><s xml:id="_8ZDKEmH">The main endpoint was daily adherence (the efficacy of the investigated interventions was measured by this variable).</s></p><p xml:id="_dW9z5Ye"><s xml:id="_n5fVBxG">We calculated the relevance of the intervention made by reducing the absolute risk (ARR), the relative risk reduction (RRR) and the number of patients needed to treat to avoid non-adherence (NNT ¼ 1/ARR).</s></p><p xml:id="_WfvTvyH"><s xml:id="_m7bqsXV">Different non-adherence patterns were defined <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> according to AP as: adherencea) absolute adherence with AP of 100%, b) masked adherence with AP &gt;80% and daily AP of &lt;80%, c) adherence with sporadic non-adherence when AP &gt;80% and less than 100%, and d) over-adherence with AP &gt;100%; non-adherencea) absolute non-adherence when AP &lt;50%, b) partial non-adherence when AP between 50% and 80%, c) treatment abandonment when the patient stopped taking the medication (as declared by the patient and as recorded in MEMS); other patterns (adherents or non adherents) -a) pharmacological holidays of at least 3 days without taking the medication, b) schedule/time non-adherence when the medication was not taken between 7 and 9 am, c) mixed non-adherence when two or more non-adherence patterns were met and d) white robe adherence, when the medication was taken the days before and after the visit, with non-adherence the rest of the time.</s></p><p xml:id="_d3gWFuA"><s xml:id="_YZFWV3t">The following variables were also analyzed: age and sex, number of concomitant diseases, number of drugs consumed and mean BP (SBP and DBP).</s><s xml:id="_VTwWeKM">The percentage of controlled patients was also calculated (BP &lt;140 and 90 mmHg).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tE8UbuF">Statistical analysis</head><p xml:id="_2ZB9aDM"><s xml:id="_ban2np3">The variables were calculated and compared overall and by groups.</s><s xml:id="_YNrkuft">The Paradox 3.5 database and a standard statistical computer package were used.</s><s xml:id="_H2RRcmv">Chi-square test, Student's t test and McNemar test were used to compare quantitative variables for paired and unpaired data.</s><s xml:id="_nQZQ8nc">For all hypotheses tested two-tailed p values &lt;.05 were considered to be significant.</s><s xml:id="_CJPe3cc">The 95% confidence intervals were calculated.</s></p><p xml:id="_Nw2UuYx"><s xml:id="_HMGGfrM">The study was carried out following the ethical standards of the Declaration of Helsinki.</s><s xml:id="_3m2CbSV">The guidelines of the European Community and the Spanish Medicines Agency were followed.</s><s xml:id="_jgS8kQu">The study was cataloged by the Spanish Agency of Medicine as EPA-SP UN-HTA-2015-01 and was evaluated by the Coordinating Committee of Ethics of Biomedical Research of Andalusia.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8cGm3nC">Results</head><p xml:id="_bRSfhxB"><s xml:id="_vfgNmbx">A total of 154 patients were included, and 148 hypertensive patients were valid for the analysis (96.1%).</s><s xml:id="_tjgmA4U">The overall mean age was 57.5 ± 9.9 years.</s><s xml:id="_V4XxuuN">There were 71 men (47.9%) and 77 women (52.02%) (mean age: 57.9 ± 10.3 years and 57.2 ± 9.8 years respectively (p ¼ NS).</s><s xml:id="_3KSFbMu">Of the 6 patients not included (4 in IG and 2 in CG) the reasons were in 2 cases due to technical problems in the readings of the MEMSs, 2 cases did not show up to the control visits; 1 moved to another city and 1 had to abandon due to illness that required long hospitalization.</s></p><p xml:id="_GSwWvVz"><s xml:id="_2ZA95wU">Seventy-three individuals of the IG and 75 of the CG were evaluated.</s><s xml:id="_cfdYGDx">No significant differences were observed between the two groups in age, sex, number of diseases suffered, number of drugs consumed, initial weight, vascular risk factors and other alterations related to cardiovascular disease (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p xml:id="_2paHP7p"><s xml:id="_347Sjgw">Significant differences could be observed between the groups in global AP, AP of a single daily dose, AP in the correct schedule and AP of therapeutic coverage, in favor of the IG (Table <ref type="table" target="#tab_1">2</ref>).</s><s xml:id="_yaukFeS">Adherence once daily was 93.15% and 86.3% in IG and 70.66% and 62.66% in CG after 6 and 12 months, respectively, the adherence percentage being significantly higher in the IG (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p xml:id="_U7KXZFf"><s xml:id="_bc7x8xa">The mean BP was similar at the beginning in the two groups (134.7 ± 14 mmHg in IG vs. 134.47</s><s xml:id="_DRy7bUg">± 8 mmHg in CG).</s><s xml:id="_gZDCgF3">Significant differences were observed in the mean decreases in BP in the IG throughout the study (final BP: 132.2 ± 12, p &lt;.05).</s><s xml:id="_wdcwBfZ">In the CG blood pressure was not modified throughout the follow-up (134.4 ± 11 mmHg) (Table <ref type="table" target="#tab_2">3</ref>).</s></p><p xml:id="_b9FGPUd"><s xml:id="_9cuQ4sy">Regarding the control of blood pressure, in the whole group at the end of the study, 77.02% (CI ¼ 70.25-83.79) of the global sample were adherent.</s><s xml:id="_hmf3fRE">The daily AP was 74.32% (CI ¼ 67.</s><s xml:id="_99mzEFF">29-81.35).</s><s xml:id="_55mm27S">The percentage of uncontrolled BP patients at the end of the study was 28.3% (CI ¼ 21.05-35.55%).</s></p><p xml:id="_4hSBvbF"><s xml:id="_kheHtkt">The results by groups were as follows.</s><s xml:id="_QK3yaKD">At baseline 35.6% and 32% in the IG and CG respectively were controlled (p ¼ NS); at 6 months this was 20.5 and 44% (p &lt; .05)</s><s xml:id="_yKs6c5F">and finally the results were 17.8% in CG (CI ¼ 9.03-26.57)</s><s xml:id="_ThhfHa9">and 38.6% in IG (CI ¼ 27.6-49.6)</s><s xml:id="_HgtW35Q">(p &lt; .05).</s></p><p xml:id="_kdSNSev"><s xml:id="_natXhVw">The ARR at 12 months was 23.64%, giving a RRR of 63.61%.</s><s xml:id="_xXDKFHT">The NNT was calculated to be 4.23 patients.</s></p><p xml:id="_CSBavUH"><s xml:id="_8HGaSFW">When assessing the adherence patterns (Table <ref type="table" target="#tab_3">4</ref>), it can be observed that among adherents the pattern of sporadic non-adherence is the most frequent and among non-adherents, the partial default pattern predominates.</s><s xml:id="_zhBMHjN">We found other predominant patterns to be pharmacological holidays (66.3%) and non-adherence with the pill schedule (85.34%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7vGVztu">Discussion</head><p xml:id="_HAXzvfK"><s xml:id="_6qCusC3">Our study highlights high daily adherence, being 74.32% of the global sample, while non-adherence was 25.68%.</s><s xml:id="_XapuCZU">However, it has been observed that in the CG, 3 out of 10 patients stopped taking a tablet daily, and 8 out of 10 did not take the medication at the recommended time.</s></p><p xml:id="_NVD2Wh9"><s xml:id="_wS4Nh7r">In studies carried out by counting tablets or MEMSs between 1984 and 2005, non-adherence in Spain ranged between 7.1% and 66.2% with a global weighted average of 32.53% <ref type="bibr" target="#b6">7</ref> .</s></p><p xml:id="_mAfZWxJ"><s xml:id="_AcysBbe">Subsequent works, such as the 2012 CUMPLE study 8 conducted with MEMSs that assessed non-adherence at 6 months in 3900 hypertensive patients with poorly controlled blood pressure and high cardiovascular risk, found a rate of 53.5% non-adherence and in another study by M arquez Contreras et al. <ref type="bibr" target="#b21">22</ref> , on hypertensive patients treated in primary care with a follow-up of 2 years, non-adherence was 22.6%.</s><s xml:id="_RycyEdX">In other countries, non-adherence also ranged between 31.2% <ref type="bibr" target="#b11">12</ref> and 45.2% <ref type="bibr" target="#b5">6</ref> .</s><s xml:id="_E4gZ3kn">Non-adherence with other drugs such as oral anticoagulants is 26.78% <ref type="bibr" target="#b22">23</ref> .</s></p><p xml:id="_Rhz5uhD"><s xml:id="_QTuYs8h">In this study, we observed clinically relevant differences in adherence percentages between the two groups, being 23.64% higher in the IG.</s><s xml:id="_u2KfDzK">Therefore, the effectiveness of the intervention is demonstrated.</s><s xml:id="_Qgdd73c">The use of free of charge mobile apps, such as the "AlerHTA" application, whose objective is to promote health education in AHT and give reminders of appointments and medication intake, is effective and a useful strategy to improve antihypertensive drug adherence in hypertensive patients.</s></p><p xml:id="_nZdYX2g"><s xml:id="_Ye4yAQF">Clinical relevance was demonstrated after obtaining an NNT of 4.23.</s><s xml:id="_xxDbByH">In general, it is considered relevant to obtain an RRR of more than 50%, and the closer to 10 (or lower than 10) that the NNT gets, the greater the study benefit indicated.</s></p><p xml:id="_WN4DKyb"><s xml:id="_nrUmQbu">Therefore the required effort to prevent one non-adherent patient is small.</s><s xml:id="_7tSdqjU">Different studies have observed that the NNT with other adherence strategies was 2.49 in the study by M arquez Contreras et al. <ref type="bibr" target="#b23">24</ref> , 5.5 in the study by Tortajada Soriano <ref type="bibr" target="#b24">25</ref> , 4 in the study by Raigal 26 , 4.2 and 4.5 in the ETECUM study 27 through telephone and postal intervention, respectively, and 5.6 in the EAPACUM study through a home blood pressure self-measurement program <ref type="bibr" target="#b27">28</ref> .</s><s xml:id="_YvvYeFQ">In other pathologies, such as dyslipidemia, an NNT of 3.43 was obtained through telephone intervention, and 3.84 was obtained with anticoagulants <ref type="bibr" target="#b22">23</ref> .</s><s xml:id="_KfaP45N">In our study, hypertensive patients followed the indications for 12 months and achieved better adherence and better control of AHT, with a low dropout rate (only 2 patients did not show up for follow-up visits).</s></p><p xml:id="_CFNvCmP"><s xml:id="_BP8eKvM">Different studies show that the combination of drugs in a single pill, including the use of a polypill, improves adherence <ref type="bibr" target="#b11">12</ref> , and conclude that a 10% increase in their use could result in a 6.7% decrease in cardiovascular events in 10 years <ref type="bibr" target="#b28">29</ref> .</s></p><p xml:id="_jpUG2hn"><s xml:id="_vdhyz3P">The percentage of individuals with uncontrolled BP in the total group at the end of the study was 31.2%.</s><s xml:id="_FT6MYuB">Initially the values were similar between the two groups (IG and GC); at the end of the study, CG reached 17.8% while IG reached 38.6%.</s><s xml:id="_9dnK8zr">These findings indicate that, in parallel with the improvement in adherence, a reduction in BP and better control of AHT is obtained.</s></p><p xml:id="_95EWbhz"><s xml:id="_wJbuq2M">When assessing adherence patterns, it is observed that among adherent patients the pattern of adherence with sporadic non-adherence prevails, while among non-adherent patients the pattern of partial non-adherence prevails.</s><s xml:id="_AhhV3pq">Other patterns stand out, such as pharmacological holidays (66.3%) or non-adherence with the pill schedule (85.34%).</s><s xml:id="_wtyh7vh">It is important to know these patterns of non-adherence since it will need specific strategies to address them.</s></p><p xml:id="_746c89A"><s xml:id="_ACsRaNG">The data from our study could be generalizable to a large group of hypertensive patients treated in primary care, since an important sample was obtained through consecutive sampling, with a relevant number of researchers from different basic health areas.</s><s xml:id="_qH66bm9">The adherence method with MEMS has been validated with respect to blood measurements of metabolites of various drugs and has the best validation compared to other methods.</s></p><p xml:id="_9UFTUDn"><s xml:id="_SnWB8cS">It is known that this method could overestimate adherence, since it is an intervention in itself, but the intervention was the same in both the CG and the IG.</s><s xml:id="_VjYVzcV">The method is not exempt from limitations, such as technical problems with the records or their cost.</s><s xml:id="_2NpAc7q">In addition, it must be kept in mind that the opening of the container does not guarantee that the medication has been taken.</s></p><p xml:id="_jpQNkyT"><s xml:id="_3U6xVVQ">This study meets the criteria recommended by Haynes et al. <ref type="bibr" target="#b30">31</ref> for adherence studies.</s><s xml:id="_E3Ht7cc">Thus, the diagnosis of AHT has been correct and the ESH-ESC 2013 recommendations have been followed.</s><s xml:id="_w5YgmPt">The recommended method is a randomized clinical trial, checking the comparability of the groups, and assessing the results on adherence and on the disease (degree of control of the AHT), with a follow-up of at least 80% of the sample and a greater number of 50 individuals per group, and with a calculation of the magnitude of the clinical relevance (RRR, RRA and NNT), with statistical significance.</s><s xml:id="_h5NjYMH">Patients without sufficient adherence data could only have influenced the results to a small degree, since only five were excluded.</s><s xml:id="_BM7PFqE">Nonetheless, the analysis of non-evaluable patients showed that the initial characteristics were similar to those of the evaluated patients.</s></p><p xml:id="_Pnzupzy"><s xml:id="_GNVunQA">The intervention with the AlerHTA app installed on the mobile phones of hypertensive patients is effective in improving both treatment adherence, and percentage control.</s></p><p xml:id="_CsTF8s3"><s xml:id="_6e7rkTD">In terms of practical utility, we must take into account the significant clinical relevance of this intervention.</s><s xml:id="_YuQk8x3">This Results expressed in percentage and confidence intervals.</s><s xml:id="_Wzrgm9G">p value: statistically significant differences in the decreases between six (p Ã ) and twelve months (p ÃÃ ), by groups.</s><s xml:id="_CU3rSaS">Results expressed as means ± standard deviation.</s><s xml:id="_VqRp6fw">p, statistically significant differences between the two groups; p Ã , statistically significant differences in the reductions between the two groups.</s><s xml:id="_EqM7Tp6">procedure does not require previous training, it would be easy to apply in practice because the introduction of smartphone apps among hypertensive patients has already started and, in our opinion, more than 50% of hypertensive patients are currently willing to take this on.</s><s xml:id="_gJUUDp7">It could be used universally in all hypertensive patients or patients with chronic diseases, or another option would be to use these smartphone apps with non-adherent patients for a certain period of time.</s><s xml:id="_C5pBFmG">As a future line of research should be conducted studies designed with the aim of finding different intervention strategies remain effective for a long time.</s></p><p xml:id="_thezxE7"><s xml:id="_9TpFpf6">We can conclude that the intervention with the AlerHTA app installed on the mobile phones of hypertensive patients:</s></p><p xml:id="_K4ecx5K"><s xml:id="_G4Wz62a">(1) favors pharmacological therapeutic adherence; (2) improves the percentage of hypertensive patient control; (3) requires small effort to avoid one case of non-adherence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vHmBYTc">Transparency</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RW2rqHW">Declaration of funding</head><p xml:id="_mYs2m7w"><s xml:id="_vvanvUk">The study is supported by institutional grant PI-0291-2014 and grant WI203903.</s><s xml:id="_XbqzTpA">CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HSUhjdy">Declaration of financial/other relationships</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>E</head><figDesc><div><p xml:id="_UasCtPW"><s xml:id="_M4vScjD">.M.C., S.M.R., E.R.G., L.L.-G.-R., J.C.P.V., A.B.S., C.G.D., V.G.G. and N.M.C. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_ear2SJF"><s xml:id="_JjPMJSd">Descriptive and bi-variant analysis of therapeutic adherence by intervention groups and by adherence and non-adherence groups.</s></p></div></figDesc><table><row><cell>Intervention</cell><cell>Control</cell><cell>p value Ã</cell></row><row><cell>Group</cell><cell>Group</cell><cell></cell></row><row><cell>N ¼ 73</cell><cell>N ¼ 75</cell><cell></cell></row></table><note xml:id="_r9nhMEk"><p><s xml:id="_RhTpkQn">p: statistically significant differences in the decreases between groups (p value).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_FGxcNsY"><s xml:id="_6PJM8G4">Adherence percentages.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Intervention Group</cell><cell cols="2">Control Group</cell><cell cols="2">p value</cell></row><row><cell></cell><cell cols="2">N ¼ 73</cell><cell cols="2">N ¼ 75</cell><cell></cell><cell></cell></row><row><cell></cell><cell>6 months</cell><cell>12 months</cell><cell>6 months</cell><cell>12 months</cell><cell>p Ã</cell><cell>p ÃÃ</cell></row><row><cell>Percentage doses taken</cell><cell>94.2% (88.84-99.56)</cell><cell>92.8% (87.44-98.16)</cell><cell>85.06% (77-93.12)</cell><cell>82.9% (73.38-91.42)</cell><cell>&lt;.05</cell><cell>&lt;.05</cell></row><row><cell>Global adherence</cell><cell>93.15% (87.36-98.94)</cell><cell>91.78% (85.48-98.08)</cell><cell>74.66% (64.7-84.6)</cell><cell>62.66% (51.26-73.14)</cell><cell>&lt;.01</cell><cell>&lt;.01</cell></row><row><cell>Percentage of correct days</cell><cell>91.08% (84.55-97.61)</cell><cell>89.4% (82.34-96.46)</cell><cell>82.91% (73.38-91.42)</cell><cell>81.31% (72.49-90.13)</cell><cell>&lt;.05</cell><cell>&lt;.05</cell></row><row><cell>Daily adherence</cell><cell>93.15% (87.36-98.94)</cell><cell>86.3% (78.42-94.18)</cell><cell>70.66% (60.36-80.9)</cell><cell>62.66% (51.26-73.14)</cell><cell>&lt;.001</cell><cell>&lt;.001</cell></row><row><cell>Percentage correct time</cell><cell>84.78% (75.68-93.88)</cell><cell>82.3% (72.7-91.9)</cell><cell>63.4% (52.6-74.2)</cell><cell>62.2% (51.2-72.2)</cell><cell>&lt;.001</cell><cell>&lt;.001</cell></row><row><cell>Correct time adherence</cell><cell>63.01% (52.11-73.91)</cell><cell>61.64% (50.14-73.14)</cell><cell>24% (2.03-45.97)</cell><cell>14.66% (0-37.26)</cell><cell>&lt;.001</cell><cell>&lt;.001</cell></row><row><cell>Percentage therapeutic cover</cell><cell>94.7% (84.5-100)</cell><cell>93.6% (87.9-99.3)</cell><cell>87.4% (79.9-94.91)</cell><cell>87.4% (79.9-94.91)</cell><cell>&lt;.05</cell><cell>&lt;.05</cell></row><row><cell>Therapeutic cover adherence</cell><cell>98.63% (97.97-100)</cell><cell>97.26% (94.54-99.98)</cell><cell>86.66% (78.8-94.46)</cell><cell>89.33% (82.25-96.41)</cell><cell>&lt;.05</cell><cell>&lt;.05</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p xml:id="_jkzDKQM"><s xml:id="_mu8hKjX">Mean systolic and diastolic blood pressures (SBP and DBP), and their mean reductions at the start and completion of the study, comparing control and intervention groups (mmHg).</s></p></div></figDesc><table><row><cell></cell><cell>Intervention Group</cell><cell>Control Group</cell><cell>p</cell></row><row><cell></cell><cell>N ¼ 73</cell><cell>N ¼ 75</cell><cell></cell></row><row><cell>Initial SBP</cell><cell>134.7 ± 14</cell><cell>134.47 ± 8</cell><cell>.3</cell></row><row><cell>SBP 6 months</cell><cell>130.6 ± 12</cell><cell>135.2 ± 8</cell><cell>&lt;.001</cell></row><row><cell>Final SBP</cell><cell>132.2 ± 12</cell><cell>134.4 ± 11</cell><cell>&lt;.001</cell></row><row><cell>Initial DBP</cell><cell>81.64 ± 8</cell><cell>81.9 ± 6.8</cell><cell>.4</cell></row><row><cell>DBP 6 months</cell><cell>78.76 ± 8</cell><cell>82.2 ± 8</cell><cell>&lt;.001</cell></row><row><cell>Final DBP</cell><cell>78.5 ± 7</cell><cell>81.4 ± 9</cell><cell>&lt;.01</cell></row><row><cell></cell><cell cols="2">Mean decrease (mmHg) Mean decrease (mmHg)</cell><cell>p Ã</cell></row><row><cell>Initial-final SBP</cell><cell>2.5 ± 11</cell><cell>0.07 ± 8</cell><cell>&lt;.001</cell></row><row><cell>Initial-final DBP</cell><cell>3.14 ± 9</cell><cell>0.5 ± 7.1</cell><cell>&lt;.001</cell></row></table><note xml:id="_bNykrBA"><p><s xml:id="_z6Ze45S">Abbreviations.</s><s xml:id="_V7nnc2F">DBP, diastolic blood pressure; SBP, systolic blood pressure.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc><div><p xml:id="_NDqqpK7"><s xml:id="_A3p6w3v">Percentage of presentation of the different adherence patterns.</s></p></div></figDesc><table><row><cell>A) Adherence</cell><cell>74.32% (n 5 110)</cell></row><row><cell>1. Absolute adherence</cell><cell>3.64%</cell></row><row><cell>2. Masked adherence</cell><cell>16.37%</cell></row><row><cell>3. Adherent with sporadic non-adherence</cell><cell>77.27%</cell></row><row><cell>4. Over-adherence</cell><cell>2.72%</cell></row><row><cell>B) Non-adherence</cell><cell>25.68% (n 5 38)</cell></row><row><cell>1. Absolute non-adherence</cell><cell>13.16% (IC ¼8.16-18.16%)</cell></row><row><cell>2. Partial non-adherence</cell><cell>86.84% (IC ¼77.04-96.84%)</cell></row><row><cell>3. Treatment abandoned</cell><cell>0%</cell></row><row><cell>C) Other patterns</cell><cell></cell></row><row><cell>1. Estimated non-adherence (&gt; o &lt; 80%)</cell><cell>19.1%</cell></row><row><cell>2. Pharmacological holidays (&gt; o &lt; 80%)</cell><cell>66.3%</cell></row><row><cell>3. White robe adherence (&lt;80%)</cell><cell>7.27%</cell></row><row><cell>4. Non-adherence of intake time</cell><cell>85.34%</cell></row><row><cell>5. Mixed non-adherence (&gt; o&lt; 80%)</cell><cell>65.45%</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="168" xml:id="foot_0"><p xml:id="_TMK67kH"><s xml:id="_2FNaHnM">E. M. CONTRERAS ET AL</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_j2UJ5QG">Acknowledgements</head><p xml:id="_uTCaS22"><s xml:id="_6UnNxEE">Previous presentation: The study was presented as an oral communication at the <rs type="institution">XXIII National Meeting</rs> of the <rs type="institution">Spanish Society of Arterial Hypertension (SEH-LELHA), Zaragoza</rs>, March</s></p></div>
			</div>			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_X244CWK">The burden of hypertension and associated risk for cardiovascular mortality in China</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lewington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lacey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clarke</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamainternmed.2016.3825</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TkrR6g9">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="524" to="532" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewington S, Lacey B, Clarke R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med 2016;176:524-32</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_K7DzBg4">Adherence to antihypertensive therapy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Peacock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Krousel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wood</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.mcna.2016.08.005</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2u5anAr">Med Clin North Am</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="229" to="245" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peacock E, Krousel E, Wood M. Adherence to antihypertensive therapy. Med Clin North Am 2017;101:229-45</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_QMeG5nV">Drug adherence in hypertension</title>
		<author>
			<persName><forename type="first">M</forename><surname>Burnier</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.phrs.2017.08.015</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4U5EV9D">Pharmacol Res</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="142" to="149" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Pt B</note>
	<note type="raw_reference">Burnier M. Drug adherence in hypertension. Pharmacol Res 2017; 125(Pt B):142-9</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_SCyYyHw">Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Chobanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bakris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Black</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.hyp.0000107251.49515.c2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yTQCtMk">Hypertension</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1206" to="1252" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chobanian AV, Bakris G, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-52</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_6TkuKDP">Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</title>
		<author>
			<persName><forename type="first">R</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Peto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Macmahon</surname></persName>
		</author>
		<idno type="DOI">10.1016/0140-6736(90)90944-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QDkZYYw">Lancet</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="page" from="827" to="838" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemio- logical context. Lancet 1990;335:827-38</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_Q63VfVB">Nonadherence to antihypertensive drugs: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Abegaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shehab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Gebreyohannes</surname></persName>
		</author>
		<idno type="DOI">10.1097/md.0000000000005641</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jY9wWAK">Medicine</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page">5641</biblScope>
			<date type="published" when="2017">2017</date>
			<pubPlace>Baltimore</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e5641</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_eFPpyeq">Analysis of studies published on hypertension treatment non-compliance in Spain between 1984 and 2005</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gil</forename><surname>Guill En</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Martell</forename><surname>Claros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XYNuQdy">Aten Primaria</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="325" to="332" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez Contreras E, Gil Guill en V, Martell Claros N, et al. Analysis of studies published on hypertension treatment non-compliance in Spain between 1984 and 2005. Aten Primaria 2006;38:325-32</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_9VX88Q2">Do patients with high vascular risk take antihypertensive medication correctly? Cumple-MEMS study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De La Figuera-Von Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Franch-Nadal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pCyGKpM">Rev Esp Cardiol (Engl Ed)</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="544" to="550" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez-Contreras E, de la Figuera-Von Wichmann M, Franch- Nadal J, et al. Do patients with high vascular risk take antihyper- tensive medication correctly? Cumple-MEMS study. Rev Esp Cardiol (Engl Ed) 2012;65:544-50</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_yT9JQaW">The impact of peer support program on adherence to the treatment regimen in patients with hypertension: a randomized clinical trial study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Haidari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moeini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khosravi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mPqMtCZ">Iran J Nurs Midwifery Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="427" to="430" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Haidari A, Moeini M, Khosravi A. The impact of peer support pro- gram on adherence to the treatment regimen in patients with hypertension: a randomized clinical trial study. Iran J Nurs Midwifery Res 2017;22:427-30</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_qCbtQz4">Treatment compliance in chronic illness: Current situation and future perspectives</title>
		<author>
			<persName><forename type="first">P</forename><surname>Conthe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aliaga P Erez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.rceng.2014.03.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_edYuPT4">Rev Clin Esp</title>
		<imprint>
			<biblScope unit="volume">214</biblScope>
			<biblScope unit="page" from="336" to="344" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Conthe P, M arquez Contreras E, Aliaga P erez A, et al. Treatment compliance in chronic illness: Current situation and future per- spectives. Rev Clin Esp 2014;214:336-44</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_uadHD7N">Improving adherence with medication: a selective literature review based on the example of hypertension treatment</title>
		<author>
			<persName><forename type="first">J</forename><surname>Matthes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Albus</surname></persName>
		</author>
		<idno type="DOI">10.3238/arztebl.2014.0041</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_udEd9YH">Dtsch Arztebl Int</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="41" to="47" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Matthes J, Albus C. Improving adherence with medication: a selective literature review based on the example of hypertension treatment. Dtsch Arztebl Int 2014;111:41-7</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_FQXAcMS">The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">W</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">X</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13272</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yapsEYU">J Clin Hypertens</title>
		<imprint>
			<date type="published" when="2018-04-27">2018. 27 April 2018</date>
			<pubPlace>Greenwich</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Du LP, Cheng ZW, Zhang YX, et al. The impact of fixed-dose com- bination versus free-equivalent combination therapies on adher- ence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich) 2018: published online 27 April 2018, doi: 10.1111/ jch.13272</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_34ZXrN6">Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bobrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Springer</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2458-14-28</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_V6GDe8t">BMC Publ Health</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">28</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bobrow K, Brennan T, Springer D, et al. Efficacy of a text messag- ing (SMS) based intervention for adults with hypertension: proto- col for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trial. BMC Publ Health 2014;14:28</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_m4BSKMc">Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Heron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Smyth</surname></persName>
		</author>
		<idno type="DOI">10.1348/135910709x466063</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JbJJdAn">Br J Health Psychol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1" to="39" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heron KE, Smyth JM. Ecological momentary interventions: incorpo- rating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol 2011;14:1-39</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_paW3Rny">The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review</title>
		<author>
			<persName><forename type="first">C</forename><surname>Free</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Galli</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1001362</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Rn32vtZ">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1001362</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Free C, Phillips G, Galli L. The effectiveness of mobile-health tech- nology-based health behaviour change or disease management interventions for health care consumers: a systematic review. PLoS Med 2013;14:e1001362</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_jDrc6xQ">Effectiveness of an intervention to provide information to patients with hypertension as short text messages and reminders sent to their mobile phone</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De La Figuera Von Wichmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gil</forename><surname>Guill En</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fZDhzjG">HTA-Alert) Aten Primaria</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="399" to="405" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez Contreras E, de la Figuera von Wichmann M, Gil Guill en V, et al. Effectiveness of an intervention to provide information to patients with hypertension as short text messages and reminders sent to their mobile phone (HTA-Alert) Aten Primaria 2004;14: 399-405</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_qS9yFby">Text messaging to improve hypertension medication adherence in African Americans from primary care and emergency department settings: results from two randomized feasibility studies</title>
		<author>
			<persName><forename type="first">L</forename><surname>Buis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hirzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Dawood</surname></persName>
		</author>
		<idno type="DOI">10.2196/mhealth.6630</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_22dxc9U">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">9</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Buis L, Hirzel L, Dawood RM, et al. Text messaging to improve hypertension medication adherence in African Americans from pri- mary care and emergency department settings: results from two randomized feasibility studies. JMIR Mhealth Uhealth 2017;5:e9</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_qmA7Tht">A content analysis of smartphone-based applications for hypertension management</title>
		<author>
			<persName><forename type="first">N</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Khunger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Garg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jash.2014.12.001</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hESVr9T">J Am Soc Hypertens</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="130" to="136" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kumar N, Khunger M, Gupta A, Garg N. A content analysis of smartphone-based applications for hypertension management. J Am Soc Hypertens 2015;9:130-6</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_H9Sq4HK">BP here, there, and everywheremobile health applications (apps) and hypertension care</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Green</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jash.2014.12.010</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6eaBqvr">J Am Soc Hypertens</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="137" to="139" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Green BB. BP here, there, and everywhere -mobile health applica- tions (apps) and hypertension care. J Am Soc Hypertens 2015;9: 137-9</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_Bydm3X2">Supporting the self-management of hypertension: patients&apos; experiences of using a mobile phone-based system</title>
		<author>
			<persName><forename type="first">I</forename><surname>Hallberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ranerup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kjellgren</surname></persName>
		</author>
		<idno type="DOI">10.1038/jhh.2015.37</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_krZsmf3">J Hum Hypertens</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="141" to="146" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hallberg I, Ranerup A, Kjellgren K. Supporting the self-manage- ment of hypertension: patients&apos; experiences of using a mobile phone-based system. J Hum Hypertens 2016;30:141-6</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_X7tHJbP">Smartphone apps for improving medication adherence in hypertension: patients&apos; perspectives</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Morrissey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Casey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Glynn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6p4Yj2C">Patient Pref Adher</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="813" to="822" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Morrissey EC, Casey M, Glynn LG, et al. Smartphone apps for improving medication adherence in hypertension: patients&apos; per- spectives. Patient Pref Adher 2018;12:813-22</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_QJ9bQpn">Validation of the electronic prescription as a method for measuring treatment adherence in hypertension</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Opez Garc Ia Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Martell</forename><surname>Claros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_P6VFhkm">Patient Educ Couns</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="1654" to="1660" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez Contreras E, L opez Garc ıa Ramos L, Martell Claros N, et al. Validation of the electronic prescription as a method for measuring treatment adherence in hypertension. Patient Educ Couns 2018;101:1654-1660</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_AVTqQVJ">Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (Facilita Study)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Martell Claros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Arquez Rivero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gC97t6A">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez Contreras E, Martell Claros N, M arquez Rivero S, et al. Strategies for improving dabigatran adherence for stroke preven- tion in patients with non-valvular atrial fibrillation: education and drug intake reminders (Facilita Study). Curr Med Res Opin 2018;21: 1-8</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_qKd8xRr">Treatment compliance in arterial hypertension. A 2-year intervention trial through health education</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Casado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Celotti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qtkC7Rc">Aten Primaria</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="5" to="9" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez Contreras E, Casado JJ, Celotti B, et al. Treatment compli- ance in arterial hypertension. A 2-year intervention trial through health education. Aten Primaria 2000;26:5-9</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<author>
			<persName><forename type="first">Tortajada</forename><surname>Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
		<title level="m" xml:id="_hTqCnXT">Efecto de la entrevista cl ınica motivacional en la cumplimentaci on: cambio conductual y grado de control en pacientes hipertensos</title>
		<imprint>
			<date type="published" when="2000">2000</date>
		</imprint>
		<respStmt>
			<orgName>Universidad Miguel Hern andez, Facultad de Medicina Alicante</orgName>
		</respStmt>
	</monogr>
	<note>Doctoral thesis</note>
	<note type="raw_reference">Tortajada Soriano JL. Efecto de la entrevista cl ınica motivacional en la cumplimentaci on: cambio conductual y grado de control en pacientes hipertensos (Doctoral thesis). Universidad Miguel Hern andez, Facultad de Medicina Alicante, 2000</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_tZTg4K9">Estudio de intervenci on sobre el cumplimiento terap eutico en la hipertensi on arterial</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Raigal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">F</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Llinares</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JMtqb7g">Med Clin (Barc)</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">Suppl 2</biblScope>
			<biblScope unit="page" from="122" to="125" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raigal Y, Gil VF, Llinares J, et al. Estudio de intervenci on sobre el cumplimiento terap eutico en la hipertensi on arterial. Med Clin (Barc) 2001;116(Suppl 2):122-5 172</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_5ckNQKz">Efficacy of telephone and mail intervention in patient compliance with antihypertensive drugs in hypertension. ETECUM-HTA study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Contreras Et Al 27. M Arquez Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Vegazo</forename><surname>Garc Ia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Martell</forename><surname>Claros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aCYG4ur">Blood Press</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="151" to="158" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">E. M. CONTRERAS ET AL 27. M arquez Contreras E, Vegazo Garc ıa O, Martell Claros N, et al. Efficacy of telephone and mail intervention in patient compliance with antihypertensive drugs in hypertension. ETECUM-HTA study. Blood Press 2005;14:151-8</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_vhAJ6wx">Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Martell-Claros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gil-Guill</forename><surname>En</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9FTvmZx">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="169" to="175" />
			<date type="published" when="2006-01">2006 Jan</date>
		</imprint>
	</monogr>
	<note type="raw_reference">M arquez-Contreras E, Martell-Claros N, Gil-Guill en V, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens. 2006 Jan;24:169-75.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_nVmmCx8">Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK</title>
		<author>
			<persName><forename type="first">V</forename><surname>Becerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gracia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Desai</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2014-007111</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BJP4qVp">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">7111</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Becerra V, Gracia A, Desai K, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open 2015;5:e007111</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_jDnX4ku">Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Durand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Morrissey</surname></persName>
		</author>
		<idno type="DOI">10.1097/hjh.0000000000001502</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wYWACxa">J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="2346" to="2357" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J 2017;35: 2346-357</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_4zk3nMu">Interventions for helping patients to follow prescriptions for medications (Cochrane Review)</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Haynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Mckibbon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kanani</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd000011</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_px4zRV3">The Cochrane Library</title>
		<meeting><address><addrLine>Oxford</addrLine></address></meeting>
		<imprint>
			<publisher>Update Software</publisher>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Haynes RB, McKibbon KA, Kanani R, et al. Interventions for helping patients to follow prescriptions for medications (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software, 1999</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
